Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 11:18 a.m.

    📋 CENTESSA PHARMACEUTICALS PLC (CNTA) - Regulatory Update

    Filing Date: 2022-06-30

    Accepted: 2022-06-30 16:34:36

    Event Type: Regulatory Update

    Event Details:

    Centessa Pharmaceuticals plc (CNTA) Announces Regulatory Update Centessa Pharmaceuticals plc (CNTA) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (CENTESSA PHARMACEUTICALS PLC):

    Product Type Development Stage Therapeutic Area Source
    LB101 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Alpha1 Anti-Trypsin Deficiency ClinicalTrials.gov
    ZF874 DRUG Phase PHASE1 Alpha1 Anti-Trypsin Deficiency ClinicalTrials.gov
    Lixivaptan DRUG Phase PHASE3 Polycystic Kidney Disease, Adult ClinicalTrials.gov
    CBS001 DRUG Phase PHASE1 Chronic Inflammatory Disease ClinicalTrials.gov
    SerpinPC DRUG Phase PHASE2 Hemophilia a ClinicalTrials.gov
    Placebo Tablets OTHER Phase PHASE1 Excessive Daytime Sleepiness ClinicalTrials.gov
    ORX142 Tablets DRUG Phase PHASE1 Excessive Daytime Sleepiness ClinicalTrials.gov
    No Intervention OTHER Preclinical Hemophilia a ClinicalTrials.gov
    ORX750 DRUG Phase PHASE2 Narcolepsy Type 1 ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Centessa Pharmaceuticals plc
    • CIK: 0001847903
    • Ticker Symbol: CNTA
    • Period End Date: 2022-06-30
    • Document Type: 8-K

Search

News categories